Supernus Pharmaceuticals (SUPN) Competitors $32.09 +0.64 (+2.03%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SUPN vs. JAZZ, PRGO, PCRX, NKTR, OMER, ASMB, CPIX, LLY, JNJ, and ABBVShould you be buying Supernus Pharmaceuticals stock or one of its competitors? The main competitors of Supernus Pharmaceuticals include Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Pacira BioSciences (PCRX), Nektar Therapeutics (NKTR), Omeros (OMER), Assembly Biosciences (ASMB), Cumberland Pharmaceuticals (CPIX), Eli Lilly and Company (LLY), Johnson & Johnson (JNJ), and AbbVie (ABBV). These companies are all part of the "pharmaceuticals" industry. Supernus Pharmaceuticals vs. Its Competitors Jazz Pharmaceuticals Perrigo Pacira BioSciences Nektar Therapeutics Omeros Assembly Biosciences Cumberland Pharmaceuticals Eli Lilly and Company Johnson & Johnson AbbVie Jazz Pharmaceuticals (NASDAQ:JAZZ) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, media sentiment, analyst recommendations, risk, institutional ownership, profitability and earnings. Do analysts prefer JAZZ or SUPN? Jazz Pharmaceuticals presently has a consensus price target of $184.00, indicating a potential upside of 68.61%. Supernus Pharmaceuticals has a consensus price target of $36.00, indicating a potential upside of 12.18%. Given Jazz Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Jazz Pharmaceuticals is more favorable than Supernus Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jazz Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.92Supernus Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33 Which has more risk and volatility, JAZZ or SUPN? Jazz Pharmaceuticals has a beta of 0.32, suggesting that its stock price is 68% less volatile than the S&P 500. Comparatively, Supernus Pharmaceuticals has a beta of 0.7, suggesting that its stock price is 30% less volatile than the S&P 500. Does the media refer more to JAZZ or SUPN? In the previous week, Jazz Pharmaceuticals had 2 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 6 mentions for Jazz Pharmaceuticals and 4 mentions for Supernus Pharmaceuticals. Supernus Pharmaceuticals' average media sentiment score of 0.91 beat Jazz Pharmaceuticals' score of 0.69 indicating that Supernus Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jazz Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Supernus Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals hold more shares of JAZZ or SUPN? 89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. 4.3% of Jazz Pharmaceuticals shares are owned by company insiders. Comparatively, 8.8% of Supernus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Is JAZZ or SUPN more profitable? Jazz Pharmaceuticals has a net margin of 11.86% compared to Supernus Pharmaceuticals' net margin of 9.27%. Jazz Pharmaceuticals' return on equity of 26.62% beat Supernus Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Jazz Pharmaceuticals11.86% 26.62% 9.14% Supernus Pharmaceuticals 9.27%12.23%9.17% Which has preferable earnings & valuation, JAZZ or SUPN? Jazz Pharmaceuticals has higher revenue and earnings than Supernus Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Supernus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJazz Pharmaceuticals$4.06B1.62$560.12M$7.5014.55Supernus Pharmaceuticals$661.82M2.71$73.86M$1.1128.91 SummaryJazz Pharmaceuticals beats Supernus Pharmaceuticals on 10 of the 16 factors compared between the two stocks. Get Supernus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SUPN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SUPN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SUPN vs. The Competition Export to ExcelMetricSupernus PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.80B$3.86B$5.46B$8.92BDividend YieldN/A1.16%5.24%4.04%P/E Ratio28.916.6127.0120.12Price / Sales2.7110.77380.1493.34Price / Cash7.676.5826.2128.59Price / Book1.712.657.995.57Net Income$73.86M-$109.62M$3.16B$248.40M7 Day Performance0.85%0.36%3.69%6.04%1 Month Performance-3.20%3.56%2.90%7.69%1 Year Performance22.29%26.13%34.30%20.97% Supernus Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SUPNSupernus Pharmaceuticals2.8598 of 5 stars$32.09+2.0%$36.00+12.2%+20.8%$1.80B$661.82M28.91580High Trading VolumeJAZZJazz Pharmaceuticals4.8941 of 5 stars$107.60-1.7%$184.00+71.0%+6.3%$6.62B$4.06B14.352,800PRGOPerrigo4.8428 of 5 stars$26.74-1.7%$33.00+23.4%+5.1%$3.74B$4.37B-20.418,379Analyst UpgradePCRXPacira BioSciences3.4244 of 5 stars$23.22flat$26.44+13.9%+10.3%$1.07B$700.97M-10.18720Positive NewsNKTRNektar Therapeutics4.8205 of 5 stars$23.47-5.2%$84.17+258.6%+21.3%$307.20M$98.43M-2.45220Analyst ForecastHigh Trading VolumeOMEROmeros3.2776 of 5 stars$3.08-3.8%$18.00+484.4%-20.3%$187.50MN/A-1.16210Gap DownASMBAssembly Biosciences3.7657 of 5 stars$18.56+2.3%$33.00+77.8%+40.5%$138.54M$28.52M-2.98100Trending NewsGap UpCPIXCumberland Pharmaceuticals0.5868 of 5 stars$3.04-3.5%N/A+107.5%$47.13M$37.87M-12.1680LLYEli Lilly and Company4.9839 of 5 stars$772.82-1.0%$1,011.61+30.9%-15.5%$739.87B$45.04B62.8847,000Trending NewsOptions VolumeJNJJohnson & Johnson4.8405 of 5 stars$155.23-0.5%$170.88+10.1%+6.0%$375.37B$88.82B17.27138,100Positive NewsABBVAbbVie4.9432 of 5 stars$187.44-1.0%$211.29+12.7%+12.1%$334.34B$56.33B79.7655,000Trending NewsAnalyst Revision Related Companies and Tools Related Companies JAZZ Alternatives PRGO Alternatives PCRX Alternatives NKTR Alternatives OMER Alternatives ASMB Alternatives CPIX Alternatives LLY Alternatives JNJ Alternatives ABBV Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SUPN) was last updated on 7/8/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump’s biggest move, misreportedThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Supernus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Supernus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.